Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRECOSE vs AVSOLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.
Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in patients with impaired glucose tolerance
Crohn's disease (moderate to severe, fistulizing),Pediatric Crohn's disease (moderate to severe),Ulcerative colitis (moderate to severe),Pediatric ulcerative colitis (moderate to severe),Rheumatoid arthritis (in combination with methotrexate),Ankylosing spondylitis,Psoriatic arthritis,Plaque psoriasis (chronic severe)
Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
Terminal elimination half-life is approximately 2 hours for the parent drug, but clinical effect persists due to prolonged binding to intestinal alpha-glucosidases.
Terminal elimination half-life is approximately 14–18 days (range 10–39 days) in adults. Prolonged half-life supports dosing every 8 weeks; it is influenced by inflammation and disease severity.
Not extensively metabolized; primarily excreted unchanged in the urine as active drug. Small fraction undergoes intestinal metabolism by digestive enzymes.
Infliximab is a monoclonal antibody; metabolism is via catabolism into peptides and amino acids through general protein degradation pathways (reticuloendothelial system). No involvement of CYP450 enzymes.
Primarily excreted in feces (about 85%) as unchanged drug and metabolites, with less than 2% excreted renally as active metabolites.
Primarily cleared by the reticuloendothelial system via proteolytic degradation. Minimal renal excretion (less than 1% unchanged) and no significant biliary or fecal elimination.
Low protein binding, approximately 5%, primarily to albumin.
Predominantly bound to soluble TNF-alpha; no specific plasma protein binding (e.g., albumin) is reported; the complex is cleared, so free drug binding is low.
Volume of distribution is approximately 0.3 L/kg, indicating minimal distribution into tissues and predominantly confined to extracellular fluid.
Volume of distribution is approximately 0.04–0.06 L/kg, indicating limited tissue distribution primarily within the vascular space.
Oral bioavailability is low, approximately 2%, due to local action in the gastrointestinal tract and minimal systemic absorption.
Bioavailability is 100% after intravenous infusion; no other routes are clinically relevant.
No dose adjustment recommended for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <25 m L/min/1.73 m²).
No dose adjustment required for renal impairment.
No dose adjustment recommended for mild hepatic impairment. Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); avoid use.
No formal studies; use caution in hepatic impairment.
Not recommended for pediatric patients (safety and efficacy not established).
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; approved for ages 6 years and older.
No specific dose adjustment required; monitor renal function due to age-related decline. Start at low end of dosing range (25 mg three times daily).
No specific dose adjustment; monitor for infections and adverse effects.
None.
WARNING: SERIOUS INFECTIONS and MALIGNANCY. Increased risk of serious infections (including tuberculosis, bacterial sepsis, invasive fungal infections) leading to hospitalization or death; increased risk of lymphoma and other malignancies, including fatal hepatosplenic T-cell lymphoma in adolescents and young adults with inflammatory bowel disease.
Hypoglycemia: Acarbose does not cause hypoglycemia when used alone, but may increase risk when combined with sulfonylureas or insulin. Hypoglycemic episodes should be treated with glucose (dextrose), not sucrose.,Hepatic injury: Rare cases of acute hepatitis, jaundice, and fulminant hepatic failure; monitor liver function tests.,Renal impairment: Contraindicated in patients with Cr Cl <25 m L/min.,Gastrointestinal effects: Frequently causes flatulence, diarrhea, and abdominal discomfort due to undigested carbohydrates; these effects may diminish with continued use.
Risk of serious infections (screen for latent TB and treat before initiation, monitor for active infections),Hypersensitivity reactions (including anaphylaxis, serum sickness),Hepatotoxicity (including hepatic failure, acute liver injury),Reactivation of hepatitis B virus,Hematologic toxicity (pancytopenia, leukopenia),Neurologic events (demyelinating disorders, seizure, optic neuritis),Heart failure exacerbation,Lupus-like syndrome,Immunogenicity (development of anti-drug antibodies leading to infusion reactions and loss of response),Malignancy (especially lymphoma, leukemia, melanoma, and Merkel cell carcinoma)
Hypersensitivity to acarbose or any component,Diabetic ketoacidosis,Cirrhosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction or predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Conditions that may deteriorate as a result of increased intestinal gas formation (e.g., Roemheld syndrome),Severe renal impairment (Cr Cl <25 m L/min)
History of severe hypersensitivity to infliximab or any murine proteins,Moderate to severe heart failure (NYHA class III/IV),Active serious infections (including sepsis, abscesses, tuberculosis, opportunistic infections),Concurrent use with abatacept or anakinra (increased risk of infection)
Avoid sucrose and table sugar as they may worsen GI side effects. Dietary carbohydrates increase efficacy but also GI side effects. Precose alone does not cause hypoglycemia; however, if used with insulin or sulfonylureas, hypoglycemia must be treated with glucose (dextrose) because absorption of complex sugars and sucrose is inhibited.
No known food interactions. AVSOLA is administered intravenously, and its absorption is not affected by oral intake. However, patients should maintain a balanced diet to support immune function.
Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.
AVSOLA (infliximab-axxq) is a monoclonal antibody. Ig G crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated with low risk of major malformations. Second and third trimester exposure may increase risk of fetal immunosuppression, including neonatal lymphopenia, and vaccination risks. Avascular necrosis and congenital anomalies have been reported post-marketing but causal relationship not established. Avoid live vaccines in infants exposed in utero for 6 months.
Unknown if excreted in human milk. Caution advised. M/P ratio not established.
Infliximab is excreted in breast milk in small amounts; M/P ratio (milk to plasma ratio) is approximately 0.001-0.002. Oral bioavailability in infants is low due to gastrointestinal degradation. Limited data show no adverse effects in breastfed infants. However, consider maternal dosage, infant age, and risk of immunosuppression. Benefit of breastfeeding likely outweighs minimal risk.
No dose adjustment recommended; monitor glucose control closely as pharmacokinetics may change; insulin often preferred.
Pharmacokinetics of infliximab may be altered due to increased plasma volume, renal clearance, and third-spacing during pregnancy. However, no specific dose adjustment guidelines are established. Most studies recommend maintaining standard dosing throughout pregnancy to ensure therapeutic levels. Monitor clinical response and consider therapeutic drug monitoring if needed. Postpartum, no dose adjustment required, but reassess for disease flare.
Precose (acarbose) is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is most effective for postprandial hyperglycemia. Must be taken with the first bite of each main meal. Avoid use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Can cause elevated liver enzymes; monitor LFTs every 3 months during first year. Hypoglycemia from other agents should be treated with glucose (not sucrose) because sucrase is inhibited.
AVSOLA (infliximab-axxq) is a biosimilar to Remicade. Pre-medicate with antihistamines and acetaminophen to reduce infusion reactions. Screen for latent TB (PPD or IGRA) and HBV before initiation. Do not administer live vaccines during therapy. Monitor for signs of infection, including opportunistic infections like histoplasmosis. Discontinue if symptoms of lupus-like syndrome or severe hepatotoxicity occur. Infusion reactions may occur up to 2 hours post-infusion; have emergency equipment available.
Take this medication with the first bite of each main meal.,If you experience low blood sugar, treat it with glucose tablets or milk, not fruit juice or regular soda.,Common side effects include flatulence, diarrhea, and abdominal pain, which often decrease with time.,Do not take this drug if you have severe kidney problems or certain bowel diseases.,Report any signs of liver problems (yellow skin/eyes, dark urine, abdominal pain) immediately.
AVSOLA is given as an IV infusion over at least 2 hours; you will be monitored during and after infusion.,Report any signs of allergic reaction (hives, difficulty breathing, swelling) immediately.,Seek medical help if you develop fever, chills, persistent cough, or skin changes.,Do not receive live vaccines while on AVSOLA; update vaccinations before starting.,Avoid becoming pregnant during treatment; use effective contraception.,Notify your doctor of any new or worsening symptoms, including chest pain or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRECOSE vs AVSOLA, answered by our medical review team.
PRECOSE is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.. AVSOLA is a TNF-Alpha Inhibitor that works by Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRECOSE and AVSOLA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRECOSE is: Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.. The standard adult dose of AVSOLA is: 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRECOSE and AVSOLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRECOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.. AVSOLA is classified as Category C. AVSOLA (infliximab-axxq) is a monoclonal antibody. IgG crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.